Our mission is to accelerate treatment decisions and improve patient quality of life, through pioneering antimicrobial stewardship-enabling diagnostics.

We are an award-winning diagnostics company specialising in developing novel solutions to tackle the global health threat of antimicrobial resistance.

We exist to prevent and control the spread of antimicrobial resistance worldwide by ensuring patients get the right antibiotic treatment the first time, rather than two or more days after the initial prescription, as per the current standard treatment.

Our patented Rplate diagnostic technology is based on a simple yet highly innovative concept. This involves using sensitive biosensor electrodes, modified with miniaturised hydrogel deposits laden with different antibiotics depending on the measured infection type.

Conducting a clinical feasibility study, in collaboration with the NHS, highlighted the successful detection of the optimum antibiotic for a specific infection in approximately 30 minutes. Currently, we are focused on scaling our first product for urinary tract infections, before expanding our platform capabilities to address a broader range of infectious diseases to address significant clinical needs.